Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...